Shares of BillionToOne surged 6.0% in pre-market trading to $120.73 after the molecular diagnostics company posted third-quarter results that handily topped Wall Street expectations and raised its full-year revenue outlook — a signal that demand for its cell-free DNA testing technology is accelerating faster than even management anticipated. BillionToOne Beats on Every Line and Raises Guidance Again — but at Nearly 185x Earnings, How Much Good News Is Already Priced In?
Shares jumped 6.0% in pre-market to $120.73 after BillionToOne, the fast-growing genetic testing company, delivered a third-quarter beat that extended its streak of upward guidance revisions — raising the question of whether the stock's rich valuation leaves room for error.
• Revenue Topped Estimates on Both More Tests and Higher Prices
Total revenue of $123.0 million rose 47% year over year and came in above the analyst estimate of $121.5 million.
The growth was driven by a 25% increase in total tests delivered and an 18% jump in the average selling price per test — meaning the company is selling more and getting paid more per test, a powerful combination. Diluted earnings per share of $0.32 more than doubled the consensus estimate of $0.15.
• Oncology Is the Fastest-Growing Bet — and the Most Expensive to Run
Oncology testing revenue hit $17.1 million, up 96% year over year , while prenatal testing brought in $104.3 million, up 41%. But cancer testing carries lower margins — oncology gross margin sits at just 45% versus 75% for prenatal. As oncology becomes a bigger share of revenue, the company will need to cut costs per test or lift prices to protect overall profitability.
• Guidance Goes Up for the Third Time This Year — but the Bar Keeps Rising
Management raised its 2026 revenue outlook to $460–$470 million, representing 51%–54% growth over 2025. That range started the year at $415–$430 million in January , was bumped to $450–$465 million after Q1 , held steady after Q2, and now moves higher again. Investors need Q4 revenue near $120–$129 million to hit the new target — achievable, but a slowdown from the year-over-year growth rates of earlier quarters.
• A Cash Cushion Funds the Next Product Launch, but the Valuation Demands Perfection
BillionToOne ended Q3 with $561 million in cash, earmarked to support a new cancer-monitoring test launching December 15. The stock trades at roughly 185x trailing earnings , meaning any stumble in test volume growth, insurer reimbursement, or the company's disclosed material weaknesses in internal controls could trigger a sharp re-pricing. For now, execution is outrunning expectations — the open question is whether that pace can hold.